Akums Drugs and PharmaceuticalsNSE:AKUMS +1.24%39 EBITDA Margin % is 16.00% as of Mar. 2026, which is 77% above its 10-year median of 9.06. GuruFocus rates NSE:AKUMS with a GF Score™ of 39/100. The stock has 7 warning signs investors should review. Among 953 Drug Manufacturers companies, Akums Drugs and Pharmaceuticals ranks better than 54.67% on this metric.
Akums Drugs and Pharmaceuticals (NSE:AKUMS) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Akums Drugs and Pharmaceuticals EBITDA Margin % Related Terms
Akums Drugs and Pharmaceuticals EBITDA Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Akums Drugs and Pharmaceuticals EBITDA Margin % Chart
NSE:AKUMS vs ZTS, UTHR: EBITDA Margin % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Akums Drugs and Pharmaceuticals's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Akums Drugs and Pharmaceuticals EBITDA Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Akums Drugs and Pharmaceuticals's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Akums Drugs and Pharmaceuticals's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Akums Drugs and Pharmaceuticals (NSE:AKUMS) has a EBITDA Margin % of 16.00% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Akums Drugs and Pharmaceuticals and its competitors. This is 77% above median its historical median of 9.06. According to the industry distribution chart, Akums Drugs and Pharmaceuticals ranks #432 out of 953 companies in the Drug Manufacturers industry, placing it in the top 45.3%.
Is Akums Drugs and Pharmaceuticals' EBITDA Margin % too high?
Akums Drugs and Pharmaceuticals' current EBITDA Margin % of 16.00% is 77% above median its 10-year median of 9.06. The Drug Manufacturers industry median EBITDA Margin % is 12.54. Akums Drugs and Pharmaceuticals' value of 16.00% is 27.6% above this industry median. Based on the distribution chart, Akums Drugs and Pharmaceuticals ranks #432 out of 953 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Akums Drugs and Pharmaceuticals has a GF Score™ of 39/100, reflecting its overall financial health beyond just this single metric.
How does Akums Drugs and Pharmaceuticals' EBITDA Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Akums Drugs and Pharmaceuticals ranks #432 out of 953 companies for EBITDA Margin %. This puts Akums Drugs and Pharmaceuticals in the upper half of its industry. The industry median EBITDA Margin % is 12.54. Akums Drugs and Pharmaceuticals' value of 16.00% is 27.6% above this benchmark. While the company's 10-year median is 9.06 vs. the industry median of 12.54, Akums Drugs and Pharmaceuticals has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Drug Manufacturers company?
The median EBITDA Margin % among Drug Manufacturers companies is 12.54, based on 953 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Akums Drugs and Pharmaceuticals's current EBITDA Margin % of 16.00% is 27.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Akums Drugs and Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median EBITDA Margin % is 12.54 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Akums Drugs and Pharmaceuticals's current EBITDA Margin % is 16.00%, which is 77% above median its own 10-year median of 9.06. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Akums Drugs and Pharmaceuticals stock overvalued right now?
Akums Drugs and Pharmaceuticals (NSE:AKUMS) has a current EBITDA Margin % of 16.00%. The current EBITDA Margin % is 16.00%, which is 77% above median its 10-year median of 9.06 and 27.6% above the Drug Manufacturers industry median of 12.54. Akums Drugs and Pharmaceuticals' overall GF Score™ is 39/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Akums Drugs and Pharmaceuticals (NSE:AKUMS), the current EBITDA Margin % is 16.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Akums Drugs and Pharmaceuticals Business Description
Akums Drugs and Pharmaceuticals Ltd a pharmaceutical contract development and manufacturing organization offering a comprehensive range of pharmaceutical products and services in India and overseas. Its services include formulation research and development (R&D), preparation and filing of regulatory dossiers in the Indian and Outside markets, and other testing services. It is also engaged in the manufacturing and sale of branded pharmaceutical formulations and active pharmaceutical ingredients (APIs). It operates in five segments: Contract Development and Manufacturing Operations, Active Pharmaceutical Ingredient (API), Domestic Branded formulations, International Branded Formulations, and Trade generics. Key revenue is generated from Contract Development and Manufacturing Operations.
39GF Score
Get the complete analysis for NSE:AKUMS
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:AKUMS has been successfully added to your 
